Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jutta Askergren"'
Publikováno v:
Scandinavian Journal of Haematology. 24:87-94
Immunological functions of 9 non-splenectomized and 8 splenectomized patients with Hodgkin's disease were studied before and after treatment. The two groups compared well with regard to age, clinical and immunological findings at diagnosis and observ
Publikováno v:
Scandinavian Journal of Haematology. 26:97-105
Spontaneously DNA synthesizing blood and spleen lymphocytes in 9 patients with Hodgkin's disease have been studied by surface markers and by autoradiography after in vitro labelling with 3H-thymidine of cell specimens separated according to size. The
Publikováno v:
Scandinavian Journal of Haematology. 25:51-57
Spontaneous and mitogen induced blood lymphocyte DNA synthesis was studied in relation to weight and tumor involvement of the spleen in 33 untreated patients with Hodgkin's Disease. Splenic tumor involvement was found in 14 patients. In this group th
Autor:
Nils Wilking, Anders Somell, Björn Cedermark, Ulrik Ringborg, Lars Erik Rutqvist, Ulla Glas, Hemming Johansson, Lambert Skoog, Sam Rotstein, Tolle Theve, Jutta Askergren, Marie-Louise Hjalmar
Publikováno v:
Acta Oncologica. 31:265-270
The paper presents long-term results of a randomized trial of adjuvant tamoxifen (40 mg daily for 2 or 5 years) versus surgery alone including 1 347 postmenopausal patients with histologically negative axillary nodes and a tumour diameter ≤ 30 mm.
Autor:
Marie-Louise Hjalmar, Jutta Askergren, Björn Cedermark, Lambert Skoog, Ulla Glas, Nils Wilking, Anders Somell, Sam Rotstein, Tolle Theve, Lars Erik Rutqvist, Hemming Johansson
Publikováno v:
Cancer. 66:89-96
From 1976 to 1984, 427 postmenopausal women with high-risk breast cancer (pN + or pT greater than 30 mm) were randomized between postoperative radiation therapy (RT), radiation therapy plus tamoxifen (RT-TAM), adjuvant chemotherapy (CT), or chemother
Autor:
Jutta Askergren, Sam Rotstein, Lambert Skoog, Björn Cedermark, Marie-Louise Hjalmar, Tolle Theve, Leif Perbeck, Lars Erik Rutqvist, Nils Wilking, Anders Somell, Ulrik Ringborg, Ulla Glas, Anders Mattsson
Publikováno v:
Journal of the National Cancer Institute. 83(18)
Prophylactic treatment with the anti-estrogen tamoxifen may reduce the risk of breast cancer because estrogens are thought to act as promoters in the pathogenesis of the disease. This article presents results on the incidence of contralateral new pri
Autor:
Bo Nordenskjöld, Jutta Askergren, Hemming Johansson, Tolle Theve, Ulla Glas, Lambert Skoog, Lars Erik Rutqvist, Björn Cedermark, Sten Friberg, Anders Somell
Publikováno v:
Breast Cancer Research and Treatment. 10:255-266
The paper presents interim results of an on-going randomized trial of adjuvant tamoxifen (40 mg daily for 2 years) versus no endocrine adjuvant therapy in postmenopausal women with early breast cancer. A total of 1407 patients were included in the st
Autor:
Alv Alveryd, Björn Cedermark, Leif Karnströ, Anders Somell, Nils-Olof Theve, Arne Wallgren, Jutta Askergren, Ulla Glas
Publikováno v:
Cancer. 53:1253-1255
Since 1977 patients living in Stockholm with Stage I breast cancer fulfilling specific criteria are offered breast-conserving treatment. The treatment includes a partial mastectomy and a low-axillary dissection followed by radiotherapy, 5000 rad, to
Publikováno v:
Scandinavian journal of haematology. 19(5)
Purified blood lymphocytes from 81 consecutive and previously untreated patients with Hodgkin's disease were studied in vitro. The patients were evaluated 23 to 52 months after institution of therapy and were divided into two prognostic groups: 1. Co
Autor:
Tommy Fornander, Ulla Glas, Anders Mattsson, Nils Wilking, Anders Somell, Marie-Louise Hjalmar, Jutta Askergren, LabsE. Rutqvist, Björn Cedermark, Tolle Theve, Claes Silfverswärd, Lambert Skoog
Publikováno v:
Lancet (London, England). 1(8630)
The frequency of new primary cancers was studied in 1846 postmenopausal patients included in a randomised trial of tamoxifen as an adjunct to primary surgery for early breast cancer. The median follow-up was 4.5 years (range 0.5-10.5 years). The numb